MedTrace Logo

Different Anesthesia Maintain Protocol Effect the Outcome of the Patients

NCT04443946 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-10-14

No results posted yet for this study

Summary

This prospective open-label randomized study, patients were having elective urological surgery scheduled to last longer than 1 h under necessitating general anesthesia.Group-P: (Propofol group): 3 mg kg-1 min-1 propofol was pumped continuously after endotracheal intubation. Group-PAS: (Propofol and after 20 min adding Sevoflurane group): 3 mg kg-1 min-1 propofol were pumped continuously and add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation. Group-PS: (Propofol and Sevoflurane group): 3 mg kg-1 min-1 propofol were continuously pumped after endotracheal intubation, and 1% sevoflurane was inhaled continuously at the same time. Group-S: (Sevoflurane group): 1% sevoflurane continued to maintain anesthesia after endotracheal intubation. Group-PSu: (Propofol and Sufentanil group): 3 mg kg-1 min-1 propofol, 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase

Conditions

  • Urinary Surgery
  • General Anesthesia

Interventions

DRUG

Propofol

5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.

DRUG

1% Sevoflurane

add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.

DRUG

1% Sevoflurane continue

1% sevoflurane continued to maintain anesthesia after endotracheal intubation.

DRUG

Sufentanil

0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase

DRUG

2% Sevoflurane

2% sevoflurane continued to maintain anesthesia after endotracheal intubation.

DRUG

Propofol half

2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.

Sponsors & Collaborators

  • China International Neuroscience Institution

    lead OTHER

Principal Investigators

  • Yanghai Cui · China International Neuroscience Institution

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-25
Primary Completion
2020-08-05
Completion
2020-08-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04443946 on ClinicalTrials.gov